{"entity":{"id":"nct07359066","kind":"trial","name":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SRP1020 in advanced solid tumours, run by Shanghai SciBrunch Therapeutics Co., Ltd., now recruiting.","summary":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07359066 by Shanghai SciBrunch Therapeutics Co., Ltd., with 210 participants planned, started 2026-01-08 and due to reach its primary completion in 2028-02. Interventions recorded: SRP1020.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07359066","url":"https://clinicaltrials.gov/study/NCT07359066"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07359066","phase":"1/2","setting":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","sponsor":"Shanghai SciBrunch Therapeutics Co., Ltd.","enrolled":210,"outcomes":[]},"route":"/trials/nct07359066/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}